Enjoy complimentary customisation on priority with our Enterprise License!
Gastroparesis is also known as delayed gastric emptying. It is a disorder resulting in slowing down or stopping food movement from stomach to small intestine due to improper or non-functioning of muscles in the stomach. This further results in delayed digestion. Complications of gastroparesis include dehydration, automatic loss of weight, malnutrition, and fluctuation in sugar level, which becomes hard to control. Gastroparesis is oftenly classified in two types including diabetic gastroparesis and idiopathic gastroparesis. As per NIH, about 10 men and 40 women per 100,000 people have gastroparesis in the US. Moreover, the symptoms that are found to be like gastroparesis occur in around one in four adults in the US. Consequently, such rising incidences of gastroparesis is expected to boost the drug development for gastroparesis in the forthcoming years.
According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for gastroparesis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of gastroparesis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.
According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for gastroparesis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.